Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFNβ) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. The impact of NAbs on costs has not been explored. The aim of this study was to estimate the cost of RRMS patients who develop NAbs while treated with IFNβ by the Italian National Healthcare Service (NHS) and the Italian Society perspectives.
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta
PAOLICELLI, DAMIANO;D'ONGHIA, MARIANGELA;DIRENZO, VITA;Di Lecce, V;TROIANO, Maria
2015-01-01
Abstract
Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFNβ) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. The impact of NAbs on costs has not been explored. The aim of this study was to estimate the cost of RRMS patients who develop NAbs while treated with IFNβ by the Italian National Healthcare Service (NHS) and the Italian Society perspectives.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1098301515050068-main.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
51.38 kB
Formato
Adobe PDF
|
51.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
